CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HER2 特异性 CAR-T 细胞用于实体瘤免疫治疗的研究进展
英文原题：Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.
查看英文原题
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
人表皮生长因子受体2（HER2）在多种实体瘤中高表达，其异常活化与肿瘤预后不良密切相关，因此成为当前研究的重要靶点。HER2抗体成功治疗多种HER2阳性肿瘤，促使研究者设计靶向HER2的CAR-T 细胞，用于实体瘤免疫治疗。目前CAR结构已发展至第五代，而大多数HER2 CAR-T 细胞结构是在第二代CAR架构基础上改造而来。本综述将介绍HER2 CAR-T 细胞的结构和细胞毒机制，阐明HER2 CAR-T 治疗面临的困难及优化策略，并总结近期临床应用和进展。
展开英文摘要原文
Human epidermal growth factor receptor 2 (HER2) is highly expressed in various solid tumors, and its abnormal activation is closely associated with poor tumor prognosis, establishing it as a prominent target in contemporary research. The successful clinical treatment of multiple HER2-positive tumors with HER2 antibodies has prompted researchers to design chimeric antigen receptor T (CAR-T) cells targeting HER2 for solid tumor immunotherapy.
To date, the development of CAR structures has progressed to the fifth generation, with most HER2-CAR-T cell structures being modified based on the second-generation CAR architecture. This review will delineate the structure and cytotoxic mechanism of HER2-CAR-T cells, elucidate the difficulties and optimization strategies for HER2-CAR-T cell therapy, and summarize recent clinical applications and advancements.
论文信息
- 作者
- Zhu L、Liu J、Li J、Wang N、Zhao Y、Su H
- 单位
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, Shannxi, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40469307 · DOI 10.3389/fimmu.2025.1514994
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →